#EULAR2021 live might close but there is still on demand until the 4th of July. Interested in my poster: showing that quality of life in at-risk for #RA individuals is reduced but still differ from RA.. have a look at #POS1441 New insights in "pre-disease phase" @RheumNow https://t.co/xtyEgElYkX

What kind of trials would help you in making a decision which DMARD to choose if a patient is not meeting #T2T goal? #EULAR2021 @RheumNow

Norwegian Cardio-Rheuma register review of PsA incidence 32/100,000 pyrs, 28 among 🚹 & 35 among 🚺,highest in 50-59 yo pts. MTX initiated >50% PsA cases w/in 1 yr from index date, 19% used biologic DMARDs w/in 2 yrs. Abstract #POS1041 #EULAR2021 @RheumNow https://t.co/2PGVfeoFV9 https://t.co/CT9WTzcdcc

• https://ard.bmj.com/content/80/Suppl_1/795.2.full

Italian PsABio cohort study: UST ⬆️ overall persistence vs TNFi, especially in females, in monotherapy, BMI <25 or >30 kg/m2, & UST as 2nd-line tx. At 1 year, both UST & TNFi pts showed similar cDAPSA & MDA/VLDA. Abstract #POS1021 #EULAR2021 @RheumNow https://t.co/DGRXmPiTiD https://t.co/s7zMuSBEWt

• https://ard.bmj.com/content/80/Suppl_1/778

More data from @rheum_covid presented by @mugartegil showing prognostic factors in patients with SLE & COVID-19 Factors related with poor prognosis: -Male, Age, Comorbidities -Time period (1st wave) -GC doses -Disease activity - No enough data for RTX or Beli #EULAR2021 #LUPUS https://t.co/ts8QsyR5KA

What is the highest level reaction you have seen to COVID vaccine? @RheumNow #EULAR2021

Dr Pupim presents data on GM-CSF inhibitor mavrilimumab to treat non-ventilated COVID-19 with systemic hyperinflammation 65% ⬇️ ventilation/death day 29 (p=0.02) 61% ⬇️ death day 29 (p=0.07) @RheumNow #EULAR2021 Abstr#LB0001 https://t.co/VBPyv4Kbv7

Dr Ruperto on secukinumab in ERA and JPsA subtypes of JIA. HR 0.28; 95%CI 0.13–0.63 p<0.001 for flare to week 100. 87.2%, 83.7%, 67.4%, 38.4% and 24.4% of pts achieved JIA ACR 30/50/70/90/100 @RheumNow #EULAR2021 Abstr#LB0004 https://t.co/envFupqqV2

Dr Diekmann presents on rheumatic irAEs in different cancers. More common melanoma than NSCLC. SpA most common. Occurrence associated better tumour response. Good response to immunosuppression @RheumNow #EULAR2021 Abstr#POS0293 https://t.co/0tSHSbRq40

Dr Chatzis presents risk prediction model for MALT lymphoma in Sjogrens. Cryoglobulinaemia and ESSDAI at diagnosis only predictors. AUROC 0.78 for model @RheumNow #EULAR2021 Abstr#POS0290 https://t.co/cLmiMgnpwF

Quiz yourself. Which of the following is NOT a risk factor for HCQ associated conduction abnormalities? #EULAR2021 @RheumNow

Deep learning for SLE #POS0351 👉use of AI to ID potential targets/dz pathways 👉gene ranked using metric expression & interactivity 👉many IFN and JAK/STAT genes ranked high 👉strong assc w/new pathways related to CD4+Tcell different'n, macs, denditric cells #EULAR2021 @rheumnow https://t.co/JF7NFeX4E7

Not an expert in capillaroscopy? Not an issue! https://t.co/jHNKDtafQC: an automatic image reading system able to detect: -Normal capillaries Se 79.8% Spe 82% -Megacapillaries Se 89.4% Spe 78.8% -Hemorrhages (Se 71% She 73.9%) compared to expert #POS0256 #EULAR2021 @Rheumnow https://t.co/MR8enBO0de

• Capillary.io: Capillaroscopy made quick, simple and objective

Wait, let me scan your joints first! Early arthritis clinics: US examination prior first clinical review in cohort of 163: ⬇️ ⭐️time to diag from mean 31 days to 12 ⭐️n° of clinical visits - 114 visits over a year ⭐️n° of revised diag at 1yr 5 vs 16% #POS0260 #EULAR2021 @Rheumnow https://t.co/CLkNqZUJVQ

Subclinical US enthesitis in 174 IBD patients w/ or w/out PSO: -High prevalence of structural damage ≥1 enthesis 83.4% -≥1 active enthesitis 25% in IBD + PSO: -⬆️ ≥ 1 thickened enthesis 86% vs 64% p=0.009) -⬆️of PD signal at knee examination. #POS0265 @RheumNow #EULAR2021 https://t.co/8f7G5ku1kc